Sponsors (2)
The bill would cap what public program enrollees and many other patients pay and likely lower overall U.S. drug prices by tying them to international reference levels and redirecting penalties to NIH, but it risks reducing pharmaceutical innovation, prompting price or supply responses that shift costs to employers/insurers, and creating administrative and research‑priority distortions.
Medicare, Medicaid, CHIP, VA, TRICARE and FEHB enrollees would pay no more than the annual reference price for covered drugs, reducing their out‑of‑pocket prescription costs.
Uninsured and commercially insured patients (and the broader market) would face lower drug charges because the bill anchors U.S. prices to lower international reference prices and requires manufacturers to offer drugs at the reference price to all individuals.
Taxpayers and the research community would see increased funding for drug research because civil penalties collected for noncompliance are redirected to NIH, providing additional R&D dollars without new appropriations.
Patients (especially those needing new or specialized therapies) and taxpayers could face reduced access to future drugs because manufacturers face very large penalties (five times excess receipts), which may discourage investment or delay launches.
Insurers, employers and workers could see higher premiums or cost‑shifting if manufacturers raise list prices or restrict supply to offset revenue losses from reference pricing.
HHS and state agencies would face administrative burden and regulatory complexity to set annual reference prices for every drug and assess international comparators, risking implementation delays or errors.
Based on analysis of 2 sections of legislative text.
HHS must set annual reference prices for all prescription drugs and caps retail list prices for major federal program beneficiaries at that reference, with manufacturers required to offer that price to all individuals.
Introduced May 14, 2025 by Debbie Dingell · Last progress May 14, 2025
Requires the Department of Health and Human Services to set an annual reference price for every prescription drug and caps the retail list price paid by people in major federal health programs at that reference price. Drug makers must offer their products at the reference price to all individuals (including uninsured and commercially insured), and civil penalties equal to five times excess receipts apply for violations, with penalty money directed to the National Institutes of Health for drug research.